JASN:IgA肾病的死亡率分析

2019-04-12 xing.T 网络

由此可见,与匹配对照者相比,IgAN患者的死亡率增加,每310人每年增加1例,预期寿命减少6年。

IgA肾病(IgAN)从无症状的非进展性疾病到侵袭性疾病的临床过程表现多样,最多四分之一的患者在诊断后20年内出现ESRD。尽管一些研究表明IgAN的死亡率似乎有所增加,但这些研究缺乏匹配的对照者,并未报告绝对风险。 

近日,肾脏病领域权威杂志Journal of the American Society of Nephrology上发表一篇研究文章。研究人员在瑞典进行了一项基于人群的队列研究,其中包括了1974-2011年期间经活检证实的IgAN的患者;主要结局指标是死亡和ESRD。研究人员使用来自三个国家登记册的数据,将3622名IgAN患者与18041名匹配对照者联系起来;研究人员还对2773例IgAN患者和6210名兄弟姐妹进行了兄弟姐妹分析,并进行了包含2234对配偶的分析。

在中位随访13.6岁期间,577例(1.1%)IgAN患者死亡(10.67/1000人/年),而对照人群中有2066例死亡(0.7%)(每1000人每年7.45人);这相当于风险增加了1.53倍,绝对超额死亡率为每1000人每年3.23人(相当于每310人每年增加1例)和中位数预期寿命减少6年。与兄弟姐妹和配偶的比较可见类似的风险增加。IgAN与每54个人每年的1例ESRD相关。与对照组、配偶或兄弟姐妹相比,ESRD前死亡率没有显著增加。IgAN相关ESRD患者与其他原因ESRD患者的总体死亡率无显著差异。

由此可见,与匹配对照者相比,IgAN患者的死亡率增加,每310人每年增加1例,预期寿命减少6年。 

原始出处:

Simon Jarrick,et al.Mortality in IgA Nephropathy: A Nationwide Population-Based Cohort Study.JASN,2019. https://doi.org/10.1681/ASN.2018101017

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1941370, encodeId=6b5419413e06c, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Wed Dec 04 21:00:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365507, encodeId=e2e536550e1f, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Tue Apr 30 08:46:45 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414605, encodeId=937014146056d, content=<a href='/topic/show?id=c83e94827d' target=_blank style='color:#2F92EE;'>#IgA肾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9482, encryptionId=c83e94827d, topicName=IgA肾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7c3073380, createdName=huiwelcome, createdTime=Sun Apr 14 04:00:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503925, encodeId=0ea3150392557, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Sun Apr 14 04:00:00 CST 2019, time=2019-04-14, status=1, ipAttribution=)]
    2019-12-04 chenhongpeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1941370, encodeId=6b5419413e06c, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Wed Dec 04 21:00:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365507, encodeId=e2e536550e1f, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Tue Apr 30 08:46:45 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414605, encodeId=937014146056d, content=<a href='/topic/show?id=c83e94827d' target=_blank style='color:#2F92EE;'>#IgA肾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9482, encryptionId=c83e94827d, topicName=IgA肾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7c3073380, createdName=huiwelcome, createdTime=Sun Apr 14 04:00:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503925, encodeId=0ea3150392557, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Sun Apr 14 04:00:00 CST 2019, time=2019-04-14, status=1, ipAttribution=)]
    2019-04-30 一天没事干

    很好的学习机会

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1941370, encodeId=6b5419413e06c, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Wed Dec 04 21:00:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365507, encodeId=e2e536550e1f, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Tue Apr 30 08:46:45 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414605, encodeId=937014146056d, content=<a href='/topic/show?id=c83e94827d' target=_blank style='color:#2F92EE;'>#IgA肾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9482, encryptionId=c83e94827d, topicName=IgA肾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7c3073380, createdName=huiwelcome, createdTime=Sun Apr 14 04:00:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503925, encodeId=0ea3150392557, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Sun Apr 14 04:00:00 CST 2019, time=2019-04-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1941370, encodeId=6b5419413e06c, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Wed Dec 04 21:00:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=365507, encodeId=e2e536550e1f, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Tue Apr 30 08:46:45 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414605, encodeId=937014146056d, content=<a href='/topic/show?id=c83e94827d' target=_blank style='color:#2F92EE;'>#IgA肾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9482, encryptionId=c83e94827d, topicName=IgA肾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7c3073380, createdName=huiwelcome, createdTime=Sun Apr 14 04:00:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503925, encodeId=0ea3150392557, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Sun Apr 14 04:00:00 CST 2019, time=2019-04-14, status=1, ipAttribution=)]
    2019-04-14 yibei

相关资讯

JAMA:IgA患者从皮质类固醇激素获益?那可不好说

众所周知指南推荐对IgA肾病和持续性蛋白尿的患者使用皮质类固醇激素,但是其效果仍不确定。为了评估皮质类固醇激素对于进展性IgA肾病患者的有效性和安全性,Jicheng Lv等人进行了一项随机临床试验,并将结果发表在近日的JAMA杂志上。

Am J Kidney Dis:降低IgA肾病蛋白尿:吗替麦考酚酯+泼尼松vs泼尼松孰优孰劣?

2017年6月,发表在《Am J Kidney Dis》的一项由中国科学家进行的研究,比较了吗替麦考酚酯+泼尼松vs全剂量泼尼松对活动性增生病变的IgA肾病患者在降低蛋白尿方面的作用。

从黄蜀葵花中挖掘出新价值-IgA肾病治疗项目获2016年度国家科技进步一等奖

日前,由中国工程院院士陈香美领衔,中国人民解放军总医院和苏中药业集团等单位联合完成的“IgA肾病中西医结合证治规律与诊疗关键技术的创研及应用”项目获得2016年度国家科技进步奖一等奖。

罹患 ​IgA肾病,该如何治疗?

IgA肾病是指肾小球系膜区以IgA沉积为主的原发性肾小球肾炎,是我国最常见的原发性肾小球肾炎。“IgA肾病”是一个病理学名词,只有肾穿肾组织病理学才能确定诊断,其病理表现为轻度膜增生性IgA肾炎、毛细血管内增生性肾炎、新月体性肾炎等。IgA肾病的病因IgA是一种免疫球蛋白,主要分布在呼吸道粘膜、消化道粘膜和尿道粘膜等,类似于“边防军”,司职表面免疫,相当于人体防御的第一道防线。反复的呼吸道、消化道

JASN:MBL对IgA肾病预后的预测价值

众所周知IgA肾病是我国最常见的血尿原因,其特点是感染伴随偶发肉眼血尿。而甘露糖结合凝集素(MBL)不足与许多疾病的反复感染有关,在其在IgA肾病中所扮演的角色还有所争议。近日在JASN上发表的一篇文章则探讨了MBL对于IgA肾病预后的预测价值。

JASN:缓解血尿改善IgA肾病患者的肾脏存活!

由此可见,缓解血尿可能对IgA肾病的预后具有较好的效应。